The adjuvant setting for resected stage IB-IIIA NSCLC is one of the last untouched spaces for targeted and immunotherapy. In ADAURA, these patients were randomized to receive adjuvant osimertinib (an irreversible EGFR-TKI) or placebo after optional adjuvant chemotherapy. Because AstraZeneca announced that the trial has been unblinded based on recommendation from the data monitoring committee, our bets are on a significant improvement in disease-free survival. The Betting Line: Adjuvant osimertinib will significantly improve disease-free survival for patient with resected, EGFR-mutated NSCLC. | Herbst, ASCO 2020


Popular Posts